CAR-T vaccine study pulled before it began
NCT ID NCT07071909
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?